These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 17706711

  • 1. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [Abstract] [Full Text] [Related]

  • 2. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW, Small EJ.
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [Abstract] [Full Text] [Related]

  • 3. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.
    Cancer; 2004 Aug 01; 101(3):541-9. PubMed ID: 15274067
    [Abstract] [Full Text] [Related]

  • 4. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep 01; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 5. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
    Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L.
    J Urol; 2010 Sep 01; 184(3):918-23. PubMed ID: 20643458
    [Abstract] [Full Text] [Related]

  • 6. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL.
    J Clin Oncol; 2005 Nov 01; 23(31):7897-903. PubMed ID: 16258089
    [Abstract] [Full Text] [Related]

  • 7. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Nov 01; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 9. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K.
    BJU Int; 2007 Oct 15; 100(4):749-54. PubMed ID: 17822455
    [Abstract] [Full Text] [Related]

  • 10. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec 15; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 11. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May 15; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

  • 12. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov 15; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 13. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS.
    Urol Clin North Am; 2004 May 15; 31(2):331-52. PubMed ID: 15123412
    [Abstract] [Full Text] [Related]

  • 14. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.
    Int J Urol; 2007 Dec 15; 14(12):1071-5. PubMed ID: 18036042
    [Abstract] [Full Text] [Related]

  • 15. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S, DjeDjos S, Alferos G, Deprisco C.
    Prostate Cancer Prostatic Dis; 2006 Dec 15; 9(1):35-8. PubMed ID: 16276350
    [Abstract] [Full Text] [Related]

  • 16. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.
    J Urol; 2003 Jun 15; 169(6):2008-12. PubMed ID: 12771706
    [Abstract] [Full Text] [Related]

  • 17. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J, Maricić A, Valencić M, Oguić R, Krpina K, Protić A, Ivancić A, Bobinac M, Fuckar D, Vojniković B.
    Coll Antropol; 2008 Oct 15; 32 Suppl 2():79-81. PubMed ID: 19138011
    [Abstract] [Full Text] [Related]

  • 18. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA.
    J Urol; 2007 Jan 15; 177(1):17-24. PubMed ID: 17161994
    [Abstract] [Full Text] [Related]

  • 19. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR.
    Cancer; 2003 Feb 01; 97(3 Suppl):789-95. PubMed ID: 12548577
    [Abstract] [Full Text] [Related]

  • 20. The cost of treating skeletal-related events in patients with prostate cancer.
    Lage MJ, Barber BL, Harrison DJ, Jun S.
    Am J Manag Care; 2008 May 01; 14(5):317-22. PubMed ID: 18471035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.